[go: up one dir, main page]

AU2001294602A1 - Chromium containing compositions for the treatment of diabetes, the reduction of body fat, improvement of insulin sensitivity and reduction of hyperglycemia and hypercholesteremia - Google Patents

Chromium containing compositions for the treatment of diabetes, the reduction of body fat, improvement of insulin sensitivity and reduction of hyperglycemia and hypercholesteremia

Info

Publication number
AU2001294602A1
AU2001294602A1 AU2001294602A AU9460201A AU2001294602A1 AU 2001294602 A1 AU2001294602 A1 AU 2001294602A1 AU 2001294602 A AU2001294602 A AU 2001294602A AU 9460201 A AU9460201 A AU 9460201A AU 2001294602 A1 AU2001294602 A1 AU 2001294602A1
Authority
AU
Australia
Prior art keywords
reduction
conjugated fatty
treatment
hyperglycemia
body fat
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001294602A
Inventor
Danielle Greenberg
David P. Katz
James R. Komorowski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nutrition 21 LLC
Original Assignee
Nutrition 21 LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nutrition 21 LLC filed Critical Nutrition 21 LLC
Publication of AU2001294602A1 publication Critical patent/AU2001294602A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/32—Burseraceae (Frankincense family)
    • A61K36/324—Boswellia, e.g. frankincense
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/32—Burseraceae (Frankincense family)
    • A61K36/328—Commiphora, e.g. mecca myrrh or balm of Gilead
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/45—Ericaceae or Vacciniaceae (Heath or Blueberry family), e.g. blueberry, cranberry or bilberry
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/76—Salicaceae (Willow family), e.g. poplar
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Inorganic Chemistry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

A composition for treating insulin-dependent diabetes, reducing body fat, improving insulin sensitivity, reducing hyperglycemia, and reducing hypercholesterolemia with at least one chromium complex and a conjugated fatty acid or conjugated fatty alcohol is disclosed. A method of treating a subject suffering from insulin-dependent diabetes by administering a composition that includes at least one chromium complex and a conjugated fatty acid or conjugated fatty alcohol is similarly provided. The administration of a composition containing an effective dose of at least one chromium complex and a conjugated fatty acid or conjugated fatty alcohol for the treatment of obesity is likewise provided.
AU2001294602A 2000-09-21 2001-09-20 Chromium containing compositions for the treatment of diabetes, the reduction of body fat, improvement of insulin sensitivity and reduction of hyperglycemia and hypercholesteremia Abandoned AU2001294602A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US23447400P 2000-09-21 2000-09-21
US60/234,474 2000-09-21
US29668801P 2001-06-06 2001-06-06
US60/296,688 2001-06-06
PCT/US2001/029422 WO2002024180A2 (en) 2000-09-21 2001-09-20 Chromium containing compositions for the treatment of diabetes, the reduction of body fat, improvement of insulin sensitivity and reduction of hyperglycemia and hypercholesteremia

Publications (1)

Publication Number Publication Date
AU2001294602A1 true AU2001294602A1 (en) 2002-04-02

Family

ID=26927971

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001294602A Abandoned AU2001294602A1 (en) 2000-09-21 2001-09-20 Chromium containing compositions for the treatment of diabetes, the reduction of body fat, improvement of insulin sensitivity and reduction of hyperglycemia and hypercholesteremia

Country Status (9)

Country Link
US (4) US6809115B2 (en)
EP (1) EP1357977B1 (en)
JP (1) JP2004509143A (en)
CN (1) CN1665566A (en)
AT (1) ATE271406T1 (en)
AU (1) AU2001294602A1 (en)
DE (1) DE60104450T2 (en)
ES (1) ES2223924T3 (en)
WO (1) WO2002024180A2 (en)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999003464A1 (en) * 1997-07-14 1999-01-28 Interhealth Nutraceuticals Incorporated Hydroxycitric acid compositions, pharmaceutical and dietary supplements and food products made therefrom, and methods for their use in reducing body weight
US20030228347A1 (en) * 2000-09-12 2003-12-11 Clark George H. Amino acid chelate for the effective supplementation of calcium magnesium and potassium in the human diet
US20040157929A1 (en) * 2002-04-01 2004-08-12 Ohia Sunny E. Method for increasing serotonin levels in a person by administration of a composition incorporating(-)hydroxycitric acid, and related compositions thereof
WO2002096200A1 (en) * 2001-05-31 2002-12-05 Wisconsin Alumni Research Foundation Conjugated nonadecadienoic acid compositions
US7119110B2 (en) * 2001-10-05 2006-10-10 Interhealth Nutraceuticals Incorporated Method and composition for preventing or reducing the symptoms of insulin resistance syndrome
US6888016B2 (en) * 2001-10-16 2005-05-03 Loders Croklaan Usa Llc Mixtures for stimulating glucose up-take
US20030119913A1 (en) * 2001-12-20 2003-06-26 Ohia Sunny E. Method for increasing serotonin levels in a person by administration of a composition incorporating (-)-hydroxycitric acid, and related compositions thereof
US6974592B2 (en) * 2002-04-11 2005-12-13 Ocean Nutrition Canada Limited Encapsulated agglomeration of microcapsules and method for the preparation thereof
DE10226018A1 (en) * 2002-06-12 2003-12-24 Cognis Deutschland Gmbh Preparations with conjugated linoleic alcohol
MXPA04012394A (en) * 2002-07-01 2005-02-25 Unilever Nv Satiety inducing composition.
KR100523446B1 (en) * 2002-08-23 2005-10-25 주식회사 엠디바이오알파 Frankinsence extracts having activatory effects on 5' AMP-activated protin kinase
RU2277918C2 (en) * 2002-09-20 2006-06-20 Сергей Ростиславович Соколовский Method for treating obesity
IL152397A (en) * 2002-10-21 2009-02-11 Hadasit Med Res Service Compositions and compounds for the treatment of hyperglycemia
WO2004041251A1 (en) * 2002-11-04 2004-05-21 Ocean Nutrition Canada Limited Microcapsules having multiple shells and method for the preparation thereof
AU2003287974B2 (en) * 2002-12-20 2007-10-25 Unilever Plc Blood glucose regulating composition
US7759507B2 (en) * 2003-09-05 2010-07-20 Abbott Laboratories Lipid system and methods of use
TW200518768A (en) * 2003-11-17 2005-06-16 Pepgen Corp Methods for treatment of obesity and for promotion of weight loss
US20060029642A1 (en) 2004-08-03 2006-02-09 Dusan Miljkovic Methods and compositions for improved chromium complexes
US7297686B2 (en) * 2004-11-16 2007-11-20 Hwang David L Chromium complex with insulin-like activity
GB0426264D0 (en) * 2004-11-30 2004-12-29 Trigen Ltd Compounds
US8034450B2 (en) * 2005-01-21 2011-10-11 Ocean Nutrition Canada Limited Microcapsules and emulsions containing low bloom gelatin and methods of making and using thereof
CA2556520C (en) * 2005-01-27 2008-10-28 Ocean Nutrition Canada Ltd. Chromium-fatty acid compounds and methods of making and using thereof
DE602006011127D1 (en) * 2005-01-27 2010-01-28 Ocean Nutrition Canada Ltd Fatty Acid Benzene Derivatives and Method of Manufacture and Use Thereof
GB0514463D0 (en) 2005-01-31 2005-08-17 Loders Croklaan Bv Use of pinolenic acid
US9968120B2 (en) 2006-05-17 2018-05-15 Dsm Nutritional Products Ag Homogenized formulations containing microcapsules and methods of making and using thereof
US20070104805A1 (en) * 2005-11-01 2007-05-10 Udell Ronald G Compositions of Hoodia Gordonii and Pinolenic Acid Derivatives
WO2007109845A1 (en) * 2006-03-28 2007-10-04 Medical Therapies Limited Prophylaxis or treatment of diabetes
KR20090029699A (en) * 2006-04-07 2009-03-23 오션 뉴트리션 캐나다 리미티드 Emulsions and microcapsules with low interfacial tension material, preparation method and use method
EP2010188A4 (en) * 2006-04-26 2011-01-12 Mandrillus Pharma Llc Chromium complexes
NZ573327A (en) 2006-06-05 2012-07-27 Ocean Nutrition Canada Ltd Microcapsules with improved shells
JP5045879B2 (en) * 2006-06-07 2012-10-10 株式会社龍泉堂 A mixture having an effect of improving insulin resistance, an effect of suppressing weight gain, and an effect of preventing and improving fatty liver
WO2008000440A1 (en) * 2006-06-27 2008-01-03 Lipid Nutrition B.V. Use of a polyunsaturated fatty acid compound
JP2010509204A (en) * 2006-11-03 2010-03-25 プロノヴァ バイオファーマ ノルゲ アーエス Fatty acid alcohol
CA2675123C (en) 2007-01-10 2017-04-11 Ocean Nutrition Canada Limited Vegetarian microcapsules
CA2676977C (en) * 2007-01-31 2016-10-04 Nutrition 21, Inc. Use of chromium histidinate for treatment of cardiometabolic disorders
ITPD20070049A1 (en) * 2007-02-14 2008-08-15 Sila S R L CONJUGATED LINOLEIC ACID PRODUCT AND PROCESS FOR ITS MANUFACTURE
CA2681158C (en) 2007-03-13 2018-09-18 Nutrition 21, Inc. Methods and compositions for the sustained release of chromium
WO2009002867A2 (en) 2007-06-26 2008-12-31 Nutrition 21, Inc. Multiple unit dosage form having a therapeutic agents in combination with a nutritional supplement
JP2010202634A (en) * 2008-06-05 2010-09-16 Green Kanpo Seiyaku Kk Crude drug-containing composition and use thereof
TWI454221B (en) * 2008-07-14 2014-10-01 Composition and method for inhibiting formation of body fat
WO2010105239A1 (en) * 2009-03-13 2010-09-16 Russell Kenneth O Method for enhancing insulin mediated uptake of nutrients into cells
US9028879B2 (en) * 2009-07-01 2015-05-12 Jds Therapeutics, Llc Chromium complexes as enhancers of brain glucose transporters
CA2821807A1 (en) * 2010-12-21 2012-06-28 Nestec S.A. Methods and compositions suitable for managing blood glucose in animals
US8933022B2 (en) * 2011-03-01 2015-01-13 Jds Therapeutics, Llc Methods and compositions for the treatment and prevention Hypoglycemia and related disorders
US20130344007A1 (en) * 2012-06-26 2013-12-26 Yl Holdings, Inc. Frankincense chewing gum
CN103082298B (en) * 2013-01-17 2014-08-13 吉林省中药制剂工程研究中心有限公司 Health-care food for reducing blood glucose in assisted mode and preparation method thereof
US10631564B2 (en) 2015-06-19 2020-04-28 University Of Southern California Enterically coated microparticle compositions and methods for modified nutrient delivery
WO2016205701A1 (en) 2015-06-19 2016-12-22 University Of Southern California Enteral fast access tract platform system
EA031455B1 (en) * 2015-08-03 2019-01-31 Республиканское Государственное Предприятие На Праве Хозяйственного Ведения "Северо-Казахстанский Государственный Университет Имени Манаша Козыбаева" Emulsion medicinal product
WO2017139337A1 (en) 2016-02-11 2017-08-17 Nutrition 21, Llc Chromium containing compositions for improving health and fitness
US10925849B2 (en) 2016-03-15 2021-02-23 Queen Mary University Of London Method of treatment of obesity
US10820617B1 (en) 2018-03-29 2020-11-03 Government Of The United States, As Represented By The Secretary Of The Air Force All inclusive electrolytes, vitamins, and protein powder training supplement
CN111568889A (en) * 2020-06-12 2020-08-25 四川大学华西医院 Application of hydroxyoctadecadienoic acid in preparation of alpha-glucosidase inhibitor drugs and separation method thereof
CN115245510A (en) * 2021-04-28 2022-10-28 扬州大学 Uses of trans-10, cis-12 conjugated linoleic acid
CN120919090B (en) * 2025-10-16 2025-12-23 山东第一医科大学附属省立医院(山东省立医院) Application of guaiacol or derivative thereof in preparation of medicament for preventing or treating metabolic syndrome

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2248607A1 (en) * 1972-10-04 1974-04-11 Wacker Chemie Gmbh METHOD FOR PRODUCING POLYVINYL HALOGENIDES
US3899476A (en) 1974-04-29 1975-08-12 Westvaco Corp Process for making a methacrylic acid adduct of linoleic acid and product
US3923768A (en) 1974-11-18 1975-12-02 Westvaco Corp Treatment of tall oil fatty acids
US4056637A (en) 1976-06-08 1977-11-01 Japan Natural Food Co. Ltd. Process for preparing food products containing a lactic acid bacteria-fermented product of a cereal germ
FR2474310A1 (en) 1980-01-25 1981-07-31 Oreal STABLE SOLUTION WITH OXIDATION OF VITAMIN F AND JOJOBA OIL AND COSMETIC COMPOSITIONS CONTAINING THE SAME
USRE33988E (en) 1980-08-08 1992-07-07 The United States of America as repesented by the Secretary of Agriculture Dietary supplementation with essential metal picolinates
FR2490631A1 (en) 1980-09-24 1982-03-26 Roussel Uclaf NOVEL LIPID COMPOSITION FOR USE IN DIETETICS, REANIMATION AND THERAPEUTICS
US4954492A (en) 1983-07-08 1990-09-04 The William Seroy Group Synthetic GTF chromium material for decreasing blood lipid levels and process therefor
US5194615A (en) 1983-07-08 1993-03-16 The William Seroy Group Synthetic GTF chromium nicotinate material and its preparation
US4871768A (en) 1984-07-12 1989-10-03 New England Deaconess Hospital Corporation Dietary supplement utilizing ω-3/medium chain trigylceride mixtures
US5175156A (en) 1987-11-30 1992-12-29 Nutrition 21 Chromic picolinate treatment
US5087623A (en) 1988-05-31 1992-02-11 Nitrition 21 Chromic picolinate treatment
US5017614A (en) 1989-02-17 1991-05-21 Wisconsin Alumni Research Foundation Methods of preventing oxidation, quenching singlet oxygen and inhibiting mold growth and novel compositions therefor
US5208356A (en) 1989-02-17 1993-05-04 Wisconsin Alumni Research Foundation Octadecadienoic phospholipic esters, antioxidant and mold inhibiting compositions
US5070104A (en) 1989-02-17 1991-12-03 Wisconsin Alumni Research Foundation Methods of chelating metal and novel compositions therefor
US5087624A (en) 1989-03-21 1992-02-11 Nutrition 21 Chromic picolinate treatment
CA2011410C (en) * 1990-03-02 1996-12-31 Mikio Suzuki Method for continuous casting of steel
US5053534A (en) 1990-10-11 1991-10-01 Westvaco Corporation Process for making a dicarboxylic acid
US5194640A (en) 1991-06-10 1993-03-16 Westvaco Corporation Process for making high-purity oleic acid
US5554646A (en) 1992-04-29 1996-09-10 Wisconsin Alumni Research Foundation Method for reducing body fat in animals
US5430066A (en) 1992-04-29 1995-07-04 Wisconsin Alumni Research Foundation Methods for preventing weight loss, reduction in weight gain, and anorexia due to immune stimulation
US5428072A (en) 1992-04-29 1995-06-27 Wisconsin Alumni Research Foundation Method of increasing the efficiency of feed conversion in animals
US5674901A (en) * 1995-06-01 1997-10-07 Wisconsin Alumni Research Foundation Methods of treating animals to maintain or increase CD-4 and CD-8 cell populations
US5292538A (en) * 1992-07-22 1994-03-08 Metagenics, Inc. Improved sustained energy and anabolic composition and method of making
US5543405A (en) 1993-10-22 1996-08-06 Keown; Wendy J. Composition and method for weight reduction and long term management of obesity
US5855949A (en) 1994-01-10 1999-01-05 Mclean; Linsey Dietary system high in oil intake
US5814663A (en) 1994-08-29 1998-09-29 Wisconsin Alumni Research Foundation Method for maintaining an existing level of body fat
US5760082C1 (en) 1994-08-29 2001-03-06 Wisconsin Alumni Res Found Dietetic foods containing conjugated linoleic acids
US5890905A (en) * 1995-01-20 1999-04-06 Bergman; Marilyn M. Educational and life skills organizer/memory aid
FR2729957B1 (en) * 1995-01-31 1997-12-05 Maurel Sante ORGANOMETALLIC COMPLEXES BASED ON SITOSTEROLS AND ACYLGLYCEROLS AND PHARMACEUTICAL COMPOSITIONS AND DIETETIC PRODUCTS CONTAINING SAME.
US6329361B1 (en) 1995-05-12 2001-12-11 Nutrition 21 High-dose chromic picolinate treatment of type II diabetes
US5856149A (en) 1995-06-01 1999-01-05 Wisconsin Alumni Research Foundation Method of producing conjugated fatty acids
US5626849A (en) * 1995-06-07 1997-05-06 Reliv International, Inc. Weight loss composition for burning and reducing synthesis of fats
ES2148814T5 (en) 1995-11-14 2005-12-16 Loders Croklaan B.V. PROCEDURE FOR THE PREPARATION OF MATERIALS WITH A HIGH CONTENT OF CONJUGATED LINOLEIC ACID ISOMERS.
DK0779033T3 (en) 1995-11-14 2001-11-12 Unilever Nv Edible grease lubricants
US5804210A (en) 1996-08-07 1998-09-08 Wisconsin Alumni Research Foundation Methods of treating animals to maintain or enhance bone mineral content and compositions for use therein
US5866560A (en) * 1996-08-20 1999-02-02 Schering Ag 7α-(ξ-aminoalkyl)-estratrienes, process for their production, pharmaceutical preparations which contain these 7α-(ξ-aminoalkyl)-estratrienes as well as their use for the production of pharmaceutical agents
US5770247A (en) 1996-10-03 1998-06-23 Wisconsin Alumni Research Foundation Method of increasing the CLA content of cow's milK
JP3017108B2 (en) 1996-10-30 2000-03-06 リノール油脂株式会社 Method for producing conjugated linoleic acid
US5855917A (en) 1996-12-04 1999-01-05 Wisconsin Alumni Research Foundation Method for controlling body fat and/or body weight in animals and pharmaceutical compositions for use therein comprising 20-carbon conjugated unsaturated fatty acids
AU6141498A (en) 1997-02-04 1998-08-25 John V. Kosbab Compositions and methods for prevention and treatment of vascular degenerative diseases
US5892074A (en) 1997-02-18 1999-04-06 Seidel; Michael C. Synthesis of conjugated linoleic acid (CLA)
US6153774A (en) 1997-02-18 2000-11-28 Seidel; Michael C. Silver ion chromatography of high purity conjugated linoleic acid (CLA)
US5837733A (en) 1997-02-26 1998-11-17 Wisconsin Alumni Research Foundation Method for reducing secetion of apolipoprotein B in animals by administering conjugated linoleic acid
US5851572A (en) 1997-04-25 1998-12-22 Wisconsin Alumni Research Foundation Method of increasing fat firmness and improving meat quality in animals with conjugated linolenic acid
US6060087A (en) 1997-04-25 2000-05-09 Wisconsin Alumni Research Foundation Method of increasing fat firmness and improving meat quality in animals
US5789401A (en) 1997-08-08 1998-08-04 Nutrition 21 High-dose chromium/biotin treatment of type II diabetes
JPH11209279A (en) 1998-01-05 1999-08-03 Natural Ltd As Method for decreasing body weight and treating obesity
US6042869A (en) 1998-02-20 2000-03-28 Natural Nutrition Ltd. Bulk animal feeds containing conjugated linoleic acid
US6020377A (en) 1998-03-13 2000-02-01 Kansas State University Research Foundation Modified tall oil supplemented diet for growing-finishing pigs
US6015833A (en) 1998-03-17 2000-01-18 Conlinco., Inc. Conjugated linoleic acid compositions
US6077525A (en) 1998-04-10 2000-06-20 The George Washington University Use of conjugated linoleic acids
US6113973A (en) 1998-04-15 2000-09-05 Wisconsin Alumni Research Foundation Eggs enriched with conjugated linoleic acid
US6177580B1 (en) 1998-04-21 2001-01-23 Henkel Kommanditgesellschaft Auf Aktien Conjugated linolenic acid-based synthetic triglycerides
US6132724A (en) * 1998-04-29 2000-10-17 City Of Hope National Medical Center Allelic polygene diagnosis of reward deficiency syndrome and treatment
KR100402040B1 (en) 1998-05-04 2003-10-17 콘린코 인크. Methods of Using Isomer Enriched Conjugated Linoleic Acid Compositions
US6060514A (en) 1998-05-04 2000-05-09 Conlin Co., Inc. Isomer enriched conjugated linoleic acid compositions
US6214372B1 (en) 1998-05-04 2001-04-10 Con Lin Co., Inc. Method of using isomer enriched conjugated linoleic acid compositions
FI111513B (en) 1998-05-06 2003-08-15 Raisio Benecol Oy New phytosterol and phytostanol fatty acid ester compositions, products containing the same and processes for preparing the same
US5948772A (en) * 1998-08-28 1999-09-07 Ambi Inc. Chromium picolinate compositions and uses thereof
US5980905A (en) * 1998-08-28 1999-11-09 Ambi Inc. Chromium polynicotinate compositions and uses thereof
AU5802499A (en) * 1998-09-01 2000-03-21 Amway Corporation Diet composition and method of weight management
US6019874A (en) 1999-01-19 2000-02-01 Berg; Lloyd Separation of conjugated linoleic acids by azeotropic distillation
US6020378A (en) 1999-03-30 2000-02-01 Wisconsin Alumni Research Foundation Method for selectively altering body fat level, feed efficiently, or weight gain
US6342619B2 (en) * 1999-04-01 2002-01-29 Michael C. Seidel Synthesis of conjugated fatty acid
IL149907A0 (en) * 1999-12-16 2002-11-10 Mark Nutritionals Inc Nutritional composition, methods of producing said composition and methods of using said composition
WO2002009725A1 (en) 2000-08-02 2002-02-07 Pharmanutrients Methods and compositions for the prevention and treatment of inflamation, osteoarthritis, and other degenerative joint diseases
JP2004505041A (en) 2000-08-02 2004-02-19 ファーマニュートリエンツ Methods and compositions for the prevention and treatment of Syndrome X
AU2000265108A1 (en) 2000-08-02 2002-02-13 Pharmanutrients Methods and compositions for the attenuation and/or prevention of stress/catabolic responses
WO2002009693A1 (en) 2000-08-02 2002-02-07 Pharmanutrients Method and compositions for prevention and/or treatment of diabetes and glucose modulation

Also Published As

Publication number Publication date
CN1665566A (en) 2005-09-07
DE60104450T2 (en) 2005-09-15
EP1357977B1 (en) 2004-07-21
WO2002024180A2 (en) 2002-03-28
US20090060941A9 (en) 2009-03-05
WO2002024180A3 (en) 2003-04-24
US6809115B2 (en) 2004-10-26
US20060204518A1 (en) 2006-09-14
US20030091654A1 (en) 2003-05-15
EP1357977A2 (en) 2003-11-05
ES2223924T3 (en) 2005-03-01
JP2004509143A (en) 2004-03-25
US20060204517A1 (en) 2006-09-14
DE60104450D1 (en) 2004-08-26
US20020081315A1 (en) 2002-06-27
US20090136539A9 (en) 2009-05-28
ATE271406T1 (en) 2004-08-15

Similar Documents

Publication Publication Date Title
AU2001294602A1 (en) Chromium containing compositions for the treatment of diabetes, the reduction of body fat, improvement of insulin sensitivity and reduction of hyperglycemia and hypercholesteremia
AP2001002027A0 (en) Glucagon-like peptide -1 improves B-cell response to glucose in subjects with impaired glucose tolerance.
NO20003051L (en) Method of administration of AspB28 human insulin
BR9911656A (en) Pharmaceutical composition, processes for the prevention or treatment of diabetes in a mammal, for the prevention or treatment of diabetic complications in a mammal and for the prevention or treatment of impaired glucose tolerance in a mammal, use of an insulin sensitizer, and, process to reduce the side effects of an insulin sensitizer or / and an anoretic administered to a diabetic mammal
TW371628B (en) Composition for treating condyloma acuminata
UA32636C2 (en) Method for reducing cholesterol content in human blood serum
AU6918700A (en) Pharmaceutical compositions and methods for reducing the appearance of cellulite
SG149814A1 (en) Compositions and methods for treating diabetes
BR0015974A (en) Use of levetiracetam, pharmaceutical composition, use of a pharmaceutical composition and methods to treat a patient administered with an amount of at least one compound and a disease and to selectively potentiate the therapeutic effect of a compound
PH12020500242A1 (en) Administration of agents for the treatment of inflammation
EP0766966A3 (en) Method of treating insulin resistance
MXPA02002681A (en) Use of g(a)-linolenic acid metabolites in the manufacture of a medicament for the treatment or prevention of cancer.
NO20033617L (en) Procedure for the treatment of diabetes mellitus
AU9125798A (en) Specific saccharide compositions and methods for treating alzheimer's disease and other amyloidoses
WO2001030802A3 (en) Therapeutic treatments comprising administration of certain steroids for blood cell deficiencies
PT1001802E (en) COMBINED PHARMACEUTICAL PREPARATION UNDERSTANDING PARTIROID HORMONE AND A REBORN INHIBITOR OSSEA
KR950007848A (en) Treatment of Anxiety with (S)-(-)-α-ethyl-2-oxo-1-pyrrolidineacetamide
AU1569395A (en) Method for treatment of obesity using prolactin modulators and diet
CA2113856A1 (en) Antidiabetic Agent
SK42395A3 (en) Pharmaceutical agent for treatment or prevention of insulin-dependent diabetes mellitus, a method of producing and use thereof
WO2003043569A3 (en) Trans-10, cis-12 conjugated linoleic acid isomer for the treatment of diseases
AU2002314056A1 (en) Use of a vitamin d3 analogue for the treatment of autoimmune diabetes
RU96115219A (en) METHOD FOR TREATING PATIENTS WITH SUGAR DIABETES
NZ318272A (en) Glucocorticoid enhancement of gene expression
WO2005039627A3 (en) Therapeutic applications for c-peptide